Craig A. Collard, the Chief Executive Officer of Heron Therapeutics, Inc., has made notable stock transactions as reported in a recent SEC filing. On October 30 and 31, 2026, Collard acquired a total of 84,809 shares of the company’s common stock. This acquisition underscores his commitment to the company and its future prospects.

Heron Therapeutics, a company incorporated in Delaware, specializes in pharmaceutical preparations, as indicated by its Standard Industrial Classification. The company is listed under the ticker symbol HRTX and operates from San Diego, California. Recent filings show that Collard has been actively involved in stock transactions, with multiple filings in the past months, including a significant acquisition on October 30, 2026.

The filing reveals that Collard acquired 50,021 shares through a transaction coded as 'M' for a direct ownership increase. Additionally, he acquired 34,788 shares on October 31, 2026, also coded as 'M'. Following these transactions, Collard now holds a total of 939,557 shares of Heron Therapeutics.

These transactions may impact various stakeholders, including shareholders and potential investors, as they reflect Collard’s confidence in the company’s direction. His actions may also influence market perceptions regarding Heron Therapeutics' stability and growth potential.

Looking ahead, it remains unclear what specific actions will follow these stock acquisitions. The filing does not specify any upcoming votes or additional filings related to these transactions.